Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 4/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397530 | 0.86 | TACR1 (0.38) | TACR1DGAT1RXRARXRBRXRG | |
| SCHEMBL1969523 | 0.82 | CACNA1G (0.40) | CACNA1BCACNA1CCACNA1GF2TACR1 | |
| SCHEMBL18530409 | 0.79 | F2 (0.38) | F2DGAT1 | |
| SCHEMBL7982682 | 0.77 | F2 (0.40) | F2DGAT1 | |
| SCHEMBL22573048 | 0.76 | TRPM8 (0.37) | F2DGAT1 | |
| SCHEMBL1972119 | 0.76 | CACNA1B (0.39) | CACNA1BCACNA1CCACNA1GTACR1PSEN1 | |
| SCHEMBL29580628 | 0.75 | F2 (0.38) | F2DGAT1HDAC1HDAC8HDAC6 | |
| SCHEMBL30615551 | 0.75 | F2 (0.38) | F2DGAT1HDAC1HDAC8HDAC6 | |
| SCHEMBL4964090 | 0.75 | ALDH1A1 (0.39) | F2DGAT1 | |
| SCHEMBL11982931 | 0.74 | DGAT1 (0.32) | F2DGAT1HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | CACNA1B 582/4885CACNA1C 1256/4885CACNA1G 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.